Compare KALU & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALU | IOVA |
|---|---|---|
| Founded | 1946 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2006 | 2008 |
| Metric | KALU | IOVA |
|---|---|---|
| Price | $121.31 | $4.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $107.00 | $9.11 |
| AVG Volume (30 Days) | 205.8K | ★ 15.8M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 135.89 | 14.84 |
| EPS | ★ 6.77 | N/A |
| Revenue | ★ $1,585,900,000.00 | N/A |
| Revenue This Year | $13.37 | $49.14 |
| Revenue Next Year | $2.62 | $51.69 |
| P/E Ratio | $18.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.81 | $1.64 |
| 52 Week High | $150.00 | $5.63 |
| Indicator | KALU | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 54.58 |
| Support Level | $116.89 | $1.99 |
| Resistance Level | $136.10 | $4.34 |
| Average True Range (ATR) | 5.68 | 0.48 |
| MACD | -1.30 | 0.06 |
| Stochastic Oscillator | 20.12 | 42.91 |
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.